ArticleHearing research2014
In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity.
Article in Hearing research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review.Journal of cancer survivorship : research and practice · 2023Pooled it
- Hearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study.The Pediatric infectious disease journal · 2026Article
- Phytosterols reverse antiretroviral-induced hearing loss, with potential implications for cochlear aging.PLoS biology · 2023Article
- Vestibular Cochlear Manifestations in COVID-19 Cases.Frontiers in neurology · 2022Review
- Exploring the effects and mechanisms of organophosphorus pesticide exposure and hearing loss.Frontiers in public health · 2022Review
- Hearing Loss in Offspring Exposed to Antiretrovirals During Pregnancy and Breastfeeding.Frontiers in molecular neuroscience · 2022Article
- Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.Frontiers in cellular neuroscience · 2022Article
- A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.The Laryngoscope · 2021Review
- Cerebral Vascular Toxicity of Antiretroviral Therapy.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Review
- Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings.Frontiers in neurology · 2021Review
- Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence andInternational journal of molecular sciences · 2020Article
- HIV status and hearing loss among children between 6 and 12 years of age at a large urban health facility in south western Uganda.International journal of pediatric otorhinolaryngology · 2017Article
- Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.Antimicrobial agents and chemotherapy · 2015Article
- Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!International journal of immunopathology and pharmacologyArticle
- Audiological and electrophysiological alterations in HIV-infected individuals subjected or not to antiretroviral therapy.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Several studies have reported an increased incidence of auditory dysfunction among HIV/AIDS patients. We used auditory HEI-OC1 cells in cell viability, flow cytometry and caspases 3/7-activation studies to investigate the potential ototoxicity of fourteen HIV antiretroviral agents: Abacavir, AZT, Delavirdine, Didenosine, Efavirenz, Emtricitabine, Indinavir, Lamivudine, Nefinavir, Nevirapine, Tenofovir, Ritonavir, Stavudine and Zalcitabine, as well as combinations of these agents as used in the common anti-HIV cocktails Atripla™, Combivir™, Epzicom™, Trizivir™, and Truvada™. Our results suggested that most of the single assayed anti-HIV drugs are toxic for HEI-OC1 auditory cells. The cocktails, on the other hand, decreased auditory cells' viability with high significance, with the following severity gradient: Epzicom ∼ Trizivir >> Atripla ∼ Combivir > Truvada. Interestingly, our results suggest that Trizivir- and Epzicom-induced cell death would be mediated by a caspase-independent mechanism. l-Carnitine, a natural micronutrient known to protect HEI-OC1 cells against some ototoxic drugs as well as to decrease neuropathies associated with anti-HIV treatments, increased viability of cells treated with Lamivudine and Tenofovir as well as with the cocktail Atripla, but had only minor effects on cells treated with other drugs and drug combinations. Altogether, these results suggest that some frequently used anti-HIV agents could have deleterious effects on patients' hearing, and provide arguments in favor of additional studies aimed at elucidating the potential ototoxicity of current as well as future anti-HIV drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.